| __timestamp | Axsome Therapeutics, Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4279200 | 47795223 |
| Thursday, January 1, 2015 | 6776987 | 50426000 |
| Friday, January 1, 2016 | 21199860 | 70853000 |
| Sunday, January 1, 2017 | 19957616 | 78168000 |
| Monday, January 1, 2018 | 23495055 | 123757000 |
| Tuesday, January 1, 2019 | 53647067 | 140963000 |
| Wednesday, January 1, 2020 | 70244579 | 131773000 |
| Friday, January 1, 2021 | 58060725 | 210328000 |
| Saturday, January 1, 2022 | 57947447 | 235780000 |
| Sunday, January 1, 2023 | 97944000 | 244990000 |
| Monday, January 1, 2024 | 187077000 |
In pursuit of knowledge
In the ever-evolving world of biotechnology, research and development (R&D) investments are the lifeblood of innovation. Over the past decade, Axsome Therapeutics, Inc. and Travere Therapeutics, Inc. have demonstrated a steadfast commitment to advancing medical science. From 2014 to 2023, Axsome's R&D expenses surged by over 2,000%, reflecting their aggressive pursuit of groundbreaking treatments. Meanwhile, Travere's R&D investments grew by approximately 400%, underscoring their dedication to addressing rare diseases.
In 2023, Travere's R&D spending reached nearly 250 million, a testament to their robust pipeline and strategic focus. Axsome, not far behind, invested close to 98 million, marking their highest annual expenditure. This trend highlights the critical role of R&D in driving therapeutic advancements and improving patient outcomes. As these companies continue to innovate, their investments will likely shape the future of healthcare.
Research and Development Investment: Pfizer Inc. vs Axsome Therapeutics, Inc.
Analyzing R&D Budgets: GSK plc vs Travere Therapeutics, Inc.
Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Travere Therapeutics, Inc.
Research and Development Investment: Biogen Inc. vs Axsome Therapeutics, Inc.
Research and Development Investment: Sarepta Therapeutics, Inc. vs Travere Therapeutics, Inc.
R&D Insights: How Halozyme Therapeutics, Inc. and Travere Therapeutics, Inc. Allocate Funds
Research and Development Expenses Breakdown: Ionis Pharmaceuticals, Inc. vs Axsome Therapeutics, Inc.
Analyzing R&D Budgets: Axsome Therapeutics, Inc. vs ACADIA Pharmaceuticals Inc.
Research and Development Expenses Breakdown: Axsome Therapeutics, Inc. vs MorphoSys AG
Analyzing R&D Budgets: Axsome Therapeutics, Inc. vs Ligand Pharmaceuticals Incorporated
R&D Insights: How Axsome Therapeutics, Inc. and MiMedx Group, Inc. Allocate Funds
R&D Insights: How Iovance Biotherapeutics, Inc. and Travere Therapeutics, Inc. Allocate Funds